Smith Group Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Smith Group Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-30	Closed	-$1K	–	402
2021 Q2	$1K	Hold	30	–	–	﹤0.01%	362
2021 Q1	$1K	Sell	30 -1,000	-97%	-$27.9K	﹤0.01%	327
2020 Q4	$25K	Hold	1,030	–	–	﹤0.01%	242
2020 Q3	$43K	Hold	1,030	–	–	﹤0.01%	216
2020 Q2	$49K	Sell	1,030 -20	-2%	-$1.54K	﹤0.01%	204
2020 Q1	$66K	Hold	1,050	–	–	﹤0.01%	234
2019 Q4	$130K	Hold	1,050	–	–	0.01%	229
2019 Q3	$70K	Buy	1,050 +420	+67%	+$28.2K	﹤0.01%	257
2019 Q2	$50K	Hold	630	–	–	﹤0.01%	275
2019 Q1	$70K	Sell	630 -2,200	-78%	-$240K	﹤0.01%	281
2018 Q4	$285K	Sell	2,830 -100	-3%	-$10.4K	0.01%	217
2018 Q3	$370K	Buy	+2,930	New	+$310K	0.01%	209
2014 Q1	–	Sell	-24,455	Closed	-$1.67M	–	433
2013 Q4	$1.67M	Sell	24,455 -125	-0.5%	-$7.22K	0.06%	165
2013 Q3	$1.7M	Buy	+24,580	New	+$1.21M	0.07%	159

Other funds holding ICPT

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

EAM

EULAV Asset Management Sarasota, Florida $3.12B AUM 13.38% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Smith Group Asset Management's ICPT Position: Q3 2021 in Review

Smith Group Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2021, closing a stake of 30 shares — an estimated $1K sold.

Smith Group Asset Management first reported a position in ICPT in Q3 2013 and held it in 14 quarters. The position peaked at $1.7M in Q3 2013. 139 funds tracked by Wall St. Rank hold ICPT as of Q3 2021.

Smith Group Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
Smith Group Asset Management sold 30 Intercept Pharmaceuticals, Inc. shares in Q3 2021, an estimated $1K.
Smith Group Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2013 and held it in 14 quarters.
Smith Group Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $1.7M in Q3 2013.
139 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2021.

Based on Smith Group Asset Management's 13F filing for Q3 2021, filed 12 Nov 2021.